US14888D2080 - Common Stock - After market: 0.3 +0.01 (+1.69%)
NASDAQ:CBIO (1/27/2023, 7:00:02 PM)-0.01 (-2.99%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-14 2022-11-14/dmh | Earnings (Next) | 03-29 2023-03-29 |
Ins Owners | 17.49% | Inst Owners | 24.56% |
Market Cap | 9.29M | Shares | 31.49M |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 77.78 |
IPO | 04-12 2006-04-12 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 45 full-time employees. The company went IPO on 2006-04-12. The firm is focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems. The firm's product candidates consist of the coagulation-related assets marzeptacog alfa (activated) (MarzAA), dalcinonacog alfa (DalcA), and CB 2679d-GT. The firm's product MarzAA is a subcutaneously (SQ) administered next generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders. The firm's DalcA is a next generation SQ Factor IX product candidate for the prophylactic treatment of individuals with hemophilia B. Its CB 2679d-GT is an Adeno-associated virus (AAV)-based gene therapy construct harboring the DalcA sequence. The firm's SQ product candidates demonstrate a prolonged duration of activity enabling them to provide continuous therapeutic levels.
CATALYST BIOSCIENCES INC
611 Gateway Blvd Ste 710
South San Francisco CALIFORNIA 94080
P: 16508710761.0
CEO: Nassim Usman
Employees: 45
Website: http://www.catalystbiosciences.com/
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Here you can normally see the latest stock twits on CBIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: